# Emavusertib

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/emavusertib
Canonical HTML page: https://getbiobrief.com/entity/emavusertib

## Timeline

- **2026-12-01**: ASH Annual Meeting — Targeted presentation of initial proof-of-concept data for TakeAim CLL study.
- **2026-03-19**: Q4 Earnings Report — Reported $19.4M net income and updated clinical guidance for emavusertib.
- **2026-01-15**: PIPE Financing — Secured $20.2 million in initial proceeds with milestone-linked upside.
- **2025-11-01**: Erivedge Wind-down — Final Erivedge royalties received before the transition to Oberland.

## Recent coverage (1 stories)

### Curis Completes Strategic Pivot to Oncology Pipeline Following Erivedge Sale
2026-03-20 00:41:34 · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Curis has transitioned to a pure-play oncology developer, leveraging a $27.2 million gain from the sale of Erivedge royalties to fund its emavusertib clinical programs. With a cash runway extended into 2027, the company is prioritizing its registrational study in lymphoma while reporting high MRD conversion rates in its AML triplet therapy.
Full story: https://getbiobrief.com/story/curis-q4-2025-earnings-emavusertib-oncology-pivot

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.